MINI FUTURE LONG - ASTRAZENECA | Real-time Euronext Paris 10:29:07 03/06/2024 BST | ||
| 3.575 EUR | -2.32% |
|
| 1 month | +3.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 3.575 | -2.32% |
| 31/05/24 | 3.66 | +5.78% |
| 30/05/24 | 3.46 | +2.06% |
| 29/05/24 | 3.39 | -0.88% |
| 28/05/24 | 3.42 | -11.63% |
Real-time Euronext Paris
Last update June 03, 2024 at 10:29 am
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| K57NB | |
| ISIN | NLBNPNL2R311 |
| Date issued | 26/04/2024 |
| Strike | 9,105 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.33 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.98 € |
|---|---|
| Lowest since issue | 3.265 € |
| Spread | 0.01 € |
| Spread % | 0.28% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- K57NB Certificat